PGN-EDODM1
Nucleic Acid Target: DMPK mRNA, CUG repeat expansion, MBNL1, DMPK
PepGen
Most recent annual filing: 2026-03-04
- del-desiran AOC Ph3 toplineSep 2026del-desiran AOC Ph3 topline, Sep 2026, material
- PGN-EDODM1 toplineNov 2026PGN-EDODM1 topline, Nov 2026, thesis-defining
- PGN-EDODM1 readout2027PGN-EDODM1 readout, 2027, material
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (1 active programs)
Technology platforms
EDO
Enhanced Delivery Oligonucleotide platform leveraging cell-penetrating peptides (CPPs) conjugated to oligonucleotide therapeutics (PPMOs) to optimize tissue penetration, cellular uptake, and nuclear delivery; focus on neuromuscular and neurologic diseases including myotonic dystrophy type 1
Discontinued (1)
- PGN-EDO51 — Duchenne Muscular Dystrophy · voluntary discontinuation of DMD program announced May 28, 2025
Biotech Distilled coverage (2)
- 2026-08-07 UPDATE: PepGen (PEPG) - The DSMB Blinked First 🔒 Paid
- 2026-05-29 PepGen (PEPG) — Scientific Deep Dive for PGN-EDODM1 and the EDO Platform 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.